11 research outputs found
A 20 GeVs transparent neutrino astronomy from the North Pole?
No full textMuon neutrino astronomy is drown within a polluted atmospheric neutrino noise: indeed recent ICECUBE neutrino records at (TeVs), couldn't find any muon neutrino point source [1] being blurred by such a noisy sky. However at 24 GeV energy atmospheric muon neutrinos, while rising vertically along the terrestrial diameter, should disappear (or be severely depleted) while converting into tau flavor: any rarest vertical E-mu similar or equal to 12 GeV muon track at South Pole Deep Core volume, pointing back to North Pole, might be tracing mostly a noise-free astrophysical signal. The corresponding Deep Core 6 - 7 - 8 - 9 channels trigger maybe point in those directions and inside that energy range without much background. Analogous nu(mu) suppression do not occur so efficiently elsewhere (as SuperKamiokande) because of a much smaller volume, an un-ability to test the muon birth place, its length, its expected energy. Also the smearing of the terrestrial rotation makes Deep Core ideal: along the South-North Pole the solid angle is almost steady, the flavor nu(mu) nu(tau) conversion persist while the Earth is spinning around the stable poles-axis. Therefore Deep Core detector at South Pole, may scan at E-nu mu similar or equal to 18-27 GeV energy windows, into a narrow vertical cone Delta theta similar or equal to 30 degrees for a novel nu(mu), (nu) over bar (mu) astronomy almost noise-free, pointing back toward the North Pole. Unfortunately muon (at E, 12 GeV) trace their arrival direction mostly spread around an unique string in a zenith-cone solid angle. To achieve also an azimuth angular resolution a two string detection at once is needed. Therefore the doubling of the Deep Core string number, (two new arrays of six string each, achieving an average detection distance of 36.5 m), is desirable, leading to a larger Deep Core detection mass (more than double) and a sharper zenith and azimuth angular resolution by two-string vertical axis detection. Such an improvement may show a noise free (at least factor ten) muon neutrino astronomy. This enhancement may also be a crucial probe of a peculiar anisotropy foreseen for atmospheric anti-muon, in CPT violated physics versus conserved one, following a hint by recent Minos results
A program of music by Haydn
No full textRecorded during a live performance at Kanley Chapel, Western Michigan University on November 12, 1980, 4:00 p.m., program no. 72 of the School of Music's 1980-1981 season.Student and faculty soloists ; University Symphony Orchestra ; Herbert Butler, conductor.Symphony no. 7 (soloists: Becky Reish, violin ; Laura Darmiento, violin ; Jayne Weaver, viola ; Martha Galea, cello) -- Sinfonia concertante, op. 84 (soloists: Mary Ann Sabato Meade, violin ; Robert Humiston, oboe ; Herbert Butler, cello ; William Allgood, bassoon ; James Kent, conductor) -- Symphony no. 96
FOLLICLE-STIMULATING HORMONE INCREASES THE EXPRESSION OF TISSUE INHIBITORS OF METALLOPROTEINASES TIMP-1 AND TIMP-2 AND INDUCES TIMP-1 AP-1 SITE BINDING COMPLEX(ES) IN PREPUBERTAL RAT SERTOLI CELLS
No full textRegulation by thyroid hormone of expression of basement membrane components in rat Sertoli cells
No full text
Global DNA hypomethylation is an early event in H. pylori-related gastric carcinogenesis
No full textAntitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, and epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model
No full textOBJECTIVE: Targeting the tumor vasculature may offer an alternative or complementary therapeutic approach to targeting growth factor signaling in lung cancer. The aim of these studies was to evaluate the antitumor effects in vivo of the combination of ZD6126, a tumor-selective vascular-targeting agent; ZD1839 (gefitinib, Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor; and ionizing radiation in the treatment of non-small cell lung cancer xenograft model. METHODS: Athymic nude mice with established flank A549 human non-small cell lung cancer xenograft model xenografts were treated with fractionated radiation therapy, ZD6126, ZD1839, or combinations of each treatment. ZD6126 (150 mg/kg) was given i.p. the day after each course of radiation. Animals treated with ZD1839 received 100 mg/kg per dose per animal, 5 or 7 days/wk for 2 weeks. Immunohistochemistry was done to evaluate the effects on tumor growth using an anti-Ki67 monoclonal antibody. Effects on tumor-induced vascularization were quantified using an anti-factor VIII-related antigen monoclonal antibody. RESULTS: ZD6126 attenuated the growth of human A549 flank xenografts compared with untreated animals. Marked antitumor effects were observed when animals were treated with a combination of ZD6126 and fractionated radiation therapy with protracted tumor regression. ZD6126 + ZD1839 resulted in a greater tumor growth delay than either agent alone. Similar additive effects were seen with ZD1839 + fractionated radiation. Finally, the addition of ZD6126 to ZD1839 and radiation therapy seemed to further improve tumor growth control, with a significant tumor growth delay compared with animals treated with single agent or with double combinations. Immunohistochemistry showed that ZD1839 induced a marked reduction in A549 tumor cell proliferation. Both ZD1839 and ZD6126 treatment substantially reduced tumor-induced angiogenesis. ZD6126 caused marked vessel destruction through loss of endothelial cells and thrombosis, substantially increasing the level of necrosis seen when combined with radiation therapy. The combination of radiation therapy, ZD6126, and ZD1839 induced the greatest effects on tumor growth and angiogenesis. CONCLUSION: This first report shows that a selective vascular-targeting agent (ZD6126) + an anti-epidermal growth factor receptor agent (ZD1839) and radiation have additive in vivo effects in a human cancer model. Targeting the tumor vasculature offers an excellent strategy to enhance radiation cytotoxicity. Polytargeted therapy with agents that interfere with both growth factor and angiogenic signaling warrants further investigatio
Effects of a Pomegranate Fruit Extract rich in punicalagin on oxidation-sensitive genes and eNOS activity at sites of perturbed shear stress and atherogenesis
No full textDouble‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT‐I Study
No full textInternational audienceAIMS: To compare the effects of continuing versus discontinuing sitagliptin when initiating and intensively titrating insulin glargine.MATERIALS AND METHODS: Eligible patients had inadequately controlled type 2 diabetes on metformin (≥1500 mg/d) in combination with a dipeptidyl peptidase-4 (DPP-4) inhibitor and/or a sulphonylurea. Those on metformin + sitagliptin were directly randomized; all others were switched to metformin + sitagliptin (discontinuing other DPP-4 inhibitors and sulphonylureas) and stabilized during a run-in period. At randomization, patients were allocated to continuing sitagliptin or discontinuing sitagliptin, with both groups initiating insulin glargine and titrating to a target fasting glucose of 4.0 to 5.6 mmol/L.RESULTS: A total of 743 participants (mean glycated haemoglobin [HbA1c] 72.6 mmol/mol [8.8%], disease duration 10.8 years), were treated. After 30 weeks, the mean HbA1c and least squares (LS) mean change from baseline in HbA1c were 51.4 mmol/mol (6.85%) and -20.5 mmol/mol (-1.88%) in the sitagliptin group and 56.4 mmol/mol (7.31%) and -15.5 mmol/mol (-1.42%) in the placebo group; the difference in LS mean changes from baseline HbA1c was -5.0 mmol/mol (-0.46%; P < 0.001). The percentage of participants with HbA1c <53 mmol/mol (<7.0%) was higher (54% vs. 35%) and the mean daily insulin dose was lower (53 vs. 61 units) in the sitagliptin group. Despite lower HbA1c, event rates and incidences of hypoglycaemia were not higher in the sitagliptin group. Adverse events overall and changes from baseline in body weight were similar between the two treatment groups.CONCLUSION: When initiating insulin glargine therapy, continuation of sitagliptin, compared with discontinuation, resulted in a clinically meaningful greater reduction in HbA1c without an increase in hypoglycaemia. ClinicalTrials.gov Identifier: NCT02738879
Mathematical modelling of the loss of tissue compression responsiveness and its role in solid tumour development
No full textThis paper presents a mathematical model of normal and abnormal tissue growth. The modelling focuses on the potential role that stress responsiveness may play in causing proliferative disorders which are at the basis of the development of avascular tumours. In particular, we study how an incorrect sensing of its compression state by a cell population can represent a clonal advantage and can generate hyperplasia and tumour growth with well known characteristics such as compression of the tissue, structural changes in the extracellular matrix, change in the percentage of cell type (normal or abnormal), extracellular matrix and extracellular liquid. A spatially independent description of the phenomenon is given initially by a system of nonlinear ordinary dierential equations which is explicitly solved in some cases of biological interest showing a rst phase in which some abnormal cells simply replace the normal ones, a second phase in which the hyper-proliferation of the abnormal cells causes a progressive compression within the tissue itself, and a third phase in which the tissue reaches a compressed state, which presses on the surrounding environment. A travelling wave analysis is also performed which gives an estimate of the velocity of the growing mas
